Preimplantation Genetic Diagnosis for Beta Thalassemia

Faravareh Khordadpoor Deilamani and Mohammad Taghi Akbari

1Tehran Medical Genetics laboratory, Tehran, Iran
*Corresponding author: Tehran Medical Genetics laboratory, Tehran, Iran. Email: akbarimt@gmail.com

Abstract

Background: Beta thalassemia is an autosomal recessive genetic disease with the symptoms of severe anaemia, ineffective erythropoiesis and bone deformities. Preimplantation genetic diagnosis is a noninvasive clinical tool for couples who are at risk of affected pregnancy to have a healthy child.

Objectives: Here we report a PGD test for a couple who were heterozygous for CD36/37(-T) mutation in HBB gene and had terminated one affected pregnancy.

Methods: Haplotype analysis of 6 flanking STR markers as well as variant detection by cycle sequencing were included in our PGD test in order to investigate the status of the embryos reliably.

Results: Three out of five embryos were transferable.

Conclusions: One normal and one carrier embryo were transferred which resulted in the singleton pregnancy and the birth of a healthy girl.

Keywords: Preimplantation Genetic Diagnosis, HBB, Beta Thalassemia

1. Background

The thalassemia is a group of autosomal recessive inherited disorders caused by mutations in the α- and β-globin genes leading to decreased production of one of the globin chains of hemoglobin (Hb) (1).

Mutations in HBB gene (OMIM No. 141900) on chromosome 11p15 result in either reduced (β+) or absent (β0) β-globin chain synthesis leading to β-thalassemia (OMIM No. 613985) (1, 2) which is the most common autosomal recessive inherited disorder among hemoglobinopathies worldwide (3, 4).

Based on the nature of the HBB gene mutations, clinical features of β-thalassemia major patients (5) include severe anemia, ineffective erythropoiesis, hyperplastic erythroid marrow, osteopenia, bone deformities and organ (esp. heart and liver) damage (1, 6).

The most frequent mutations in the HBB gene are point mutations, however more rarely, the deletions of the entire β-globin gene cluster or of locus control region beta (OMIM No. 152424) are reported to be causative too (6).

Prenatal diagnosis using amniocentesis and chorionic villus sampling techniques is used throughout the world in order to prevent the birth of the HBB affected children (3). However the rate of termination of one or more pregnancy is high in some cases (5). Alternatively, Preimplantation genetic diagnosis can be used in which the healthy embryos are selected before implantation and decrease the need for pregnancy termination.

Three decades have passed from the first time that PGD was applied for human (7-11). Briefly a single cell biopsy is performed from each embryo on which the DNA analysis is carried out using different methods such as polymerase chain reaction PCR, PCR-RFLP, ARMS PCR or fluorescent in situ hybridization (FISH) (3, 12). However, one of the problems associated with PGD is the possibility of misdiagnosis due to allele drop-out (ADO) (5).

2. Objectives

Here we report a reliable PGD technique for β-thalassemia in which both cycle sequencing and linkage analysis were employed (3). This screening resulted in the birth of a carrier girl.
3. Methods

3.1. Patients

The PGD was performed for a couple (32 year old female and 39 year old male) with consanguineous marriage who were both carriers for CD36/37(-T) in HBB gene. These couple had the history of pregnancy and subsequently abortion of one affected fetus. Two cycles of PGD with 4 embryo transfer had been performed for this couple in another PGD center which did not end in pregnancy.

The informed consent for PGD testing was obtained from the couple. The study was approved by the local ethics committee.

3.2. Test Procedure

Two different tests (STR based linkage analysis and Cycle sequencing) were used to study the CD36/37(-T) mutation in HBB gene.

For linkage analysis 3 upstream (D11S1338, D11S1760 and D11S4891) and 3 downstream (D11S1871, D11S2351 and D11S4181) STR markers were included. Primer design was carried out using primer blast tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), GeneRunner software and SNPcheck website (https://genetools.org/SNPCheck/snpcheck.htm) (Table 1). Two multiplex PCR were performed to amplify the STR markers and the fragments were separated on 3130 Genetic Analyzer using GS 500 Liz size standard. The data was analyzed by GeneMarker software.

The PGD workup started with DNA sample analysis of the couple and additional family members. STR haplotyping for family members was performed, in order to identify the most informative STR markers linked to the HBB gene, to be used in the following clinical PGD cycle.

Blastomeres from 5 embryos were received from IVF center. After cell lysis and DNA extraction, whole genome amplification (WGA) was performed on each blastomere and positive and negative control samples using the Picoplex WGA kit from Rubicon Genomics. The PGD test was performed on the purified products.

Table 1. Primers Designed for Cycle Sequencing and Linkage Analysis. Forward Primers of the STR Markers Were Fluorescently Labeled with FAM.

| Sequencing primer | Primer Sequence |
|-------------------|----------------|
| CD36/37(-T)       | F: GCACGACGACTCCTGCTGCTATTTG  |
|                   | R: GTGAGCTACGACTAGTGGG         |
| Flanking STR markers |          |
| D11S1338          | F: AAGACGTTAATCTGTATATCTGAC  |
|                   | R: TTATCTAATGCTACTTATTTGAGT  |
| D11S1760          | F: TTCATCAATACAGAGTCTGAGT    |
|                   | R: AATACTGCTGACATAGACTG       |
| D11S4891          | F: TTGTGACCTGGGCTTACTGCTG    |
|                   | R: CATCTCTAAGTATACCCAGACTAG  |
| D11S1871          | F: TAAAAGAGTGGAAGCTGAGAC     |
|                   | R: AAGAGGTGAGCCGGTACGTG      |
| D11S2351          | F: ACCTACTATCATGACCAGTCTG    |
|                   | R: AGCTTCCCTGACATATCTTACG    |
| D11S4181          | F: GCCCTGGACCAAGAAGTGATG    |
|                   | R: AGTCTGGTACCCTACCCTAC      |

and two were Heterozygous for CD36/37(-T) mutation (embryos 1 and 4) in HBB gene. The other two embryos identified to be homozygous for CD36/37(-T) mutation in HBB gene (Figure 1 and 2).

One homozygous normal and one heterozygous embryos were transfered which ended in a singleton pregnancy.

PND was performed at 15th week of gestation and the conception of a female fetus which was heterozygous for CD36/37(-T) mutation was confirmed. The healthy girl was born.

5. Discussion

B-thalassemia is a hemoglobinopathy which is caused by mutations in the HBB gene (3, 13).

Prenatal diagnosis and subsequent termination of the affected pregnancy is a major alternative for high-risk couples (14).

In comparison to prenatal diagnosis, PGD is a noninvasive diagnostic tool to identify genetic disorders prior to pregnancy so reduces selective termination of the affected pregnancy and moral dilemmas (3). Since the first introduction of PGD it has been used widely to prevent the affected pregnancy of different genetic disorders (15).
However, ADO is reported as a common problem of PGD which may lead to false results in both recessive and dominant inherited disorders. In order to lower the risk of misdiagnosis, testing two cells from each embryo or increasing the informative markers at each side of the mutated gene is recommended (3, 16-18). According to the ESHRE guideline, analysis of at least two flanking markers which are closely linked to the causative gene reduces the risk of ADO from 5% to 1% (16).

Here we report a PGD test for HBB gene for a couple who were carrier for CD36/37(-T) mutation. Although the couple we studied had consanguineous marriage and both had the CD36/37(-T) mutation, but based on the family study and haplotype analysis we found that the mutation was not inherited from a common ancestor.

There was conformity between the results of the linkage analysis and cycle sequencing. Locus dropout was observed for D11S1871 in all embryos. Embryos 1 and 2 were transferred and resulted in singleton pregnancy and birth of a carrier girl.

Using both cycle sequencing and indirect analysis by 6 flanking STR markers (3 upstream and 3 downstream markers) our test was reliable and easy to interpret.

Acknowledgments

We thank the personnel of Tehran Medical Genetics Laboratory for their support. This project was financially...
supported by Tehran Medical Genetics Laboratory.

Footnotes

Authors’ Contribution: F. Khordadpoor: designed, performed, analyzed, and interpret the test, wrote the manuscript. MT Akbari: Approved the test and manuscript.

Conflict of Interests: There is no conflict of interest.

Ethical Approval: The study was approved by the local ethics committee.

Funding/Support: This project was financially supported by Tehran Medical Genetics Laboratory.

Informed Consent: The informed consent for PGD testing was obtained from the couple.

References

1. Fernandez RM, Pecina A, Lozano-Arana MD, Garcia-Lozano JC, Borrego S, Antinolo G. Novel one-step multiplex PCR-based method for HLA typing and preimplantational genetic diagnosis of beta-thalassemia. *Biomed Res Int*. 2013;2013:585106. doi: 10.1155/2013/585106. [PubMed: 23710452]. [PubMed Central: PMC3654635].

2. Hardison RC, Chui DH, Riemer CR, Miller W, Carver MF, Molchanova TP, et al. Access to a syllabus of human hemoglobin variants (1996) via the World Wide Web. *Hemoglobin*. 1998;22(2):113-27. doi: 10.3109/0363026980903236. [PubMed: 9576329].

3. Nasri NW, Jamal AR, Abdullah NC, Razi ZR, Mokhtar NM. Preimplantation genetic diagnosis for beta-thalassemia using single-cell DNA analysis for codons 17 and 26 of beta-globin gene. *Arch Med Res*. 2009;40(1):1-9. doi: 10.1016/j.arcmed.2008.10.008. [PubMed: 19064120].

4. Chamayou S, Alecci C, Ragolia C, Giambona A, Siciliano S, Maggio A, et al. Successful application of preimplantation genetic diagnosis for beta-thalassaemia and sickle cell anaemia in Italy. *Hum Reprod*. 2002;17(5):1158-65. doi: 10.1093/humrep/17.5.1158. [PubMed: 12980733].

5. Hussey ND, Davis T, Hall JR, Barry MF, Draper R, Norman RJ, et al. Preimplantation genetic diagnosis for beta-thalassaemia using sequencing of single cell PCR products to detect mutations and polymorphic loci. *Mol Hum Reprod*. 2002;8(12):1136-43. doi: 10.1093/molehr/8.12.1136. [PubMed: 12468648].

6. Shen X, Xu Y, Zhong Y, Zhou C, Zeng Y, Zhuang G, et al. Preimplantation genetic diagnosis for alpha-and beta-double thalassemia. *J Assist Reprod Genet*. 2011;28(10):957-64. doi: 10.1007/s10815-011-9595-5. [PubMed: 21667101]. [PubMed Central: PMC3220442].

7. Handsyde AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. *Nature*. 1990;344(6268):768-70. doi: 10.1038/344768a0. [PubMed: 2330030].

8. Verlinsky Y, Ginsberg N, Lifchez A, Valle J, Moise J, Strom CM. Analysis of the first polar body: preconception genetic diagnosis. *Hum Reprod*. 1990;5(7):826-9. doi: 10.1093/oxfordjournals.humrep.a137192. [PubMed: 2266156].

9. Handsyde AH, Lesko GJ, Tarin JJ, Winston RM, Hughes MR. Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis. *N Engl J Med*. 1992;327(13):905-9. doi: 10.1056/NEJM199209243271301. [PubMed: 1381054].

10. Satirapod C, Sukprasert M, Panthan B, Charoenyingwattana A, Chitayanan P, Chantrawit T, et al. Clinical utility of combined preimplantation genetic testing methods in couples at risk of passing on beta thalassemia/hemoglobin E disease: A retrospective review from a single center. *PLoS One*. 2019;14(11). e0225457. doi: 10.1371/journal.pone.0225457. [PubMed: 3175397]. [PubMed Central: PMC6872132].

11. Deugarte C, Ambartsoumyan G, Li M, Verlinsky Y, Hill D, Decherney A. Successful selection of normal embryos using PGD in a woman with spinocerebellar ataxia type 3. *Fertil Steril*. 2005;83(5):S30-1. doi: 10.1016/j.fertnstert.2005.01.077.

12. Griffin DK, Handsyde AH, Harper JC, Wilton LJ, Atkinson G, Soussis I, et al. Clinical experience with preimplantation diagnosis of sex by dual fluorescent in situ hybridization. *J Assist Reprod Genet*. 1994;11(3):332-43. doi: 10.1007/BF02332090. [PubMed: 7827442].
13. Kokkali G, Traeger-Synodinos J, Vrettou C, Stavrou D, Jones GM, Cram DS, et al. Blastocyst biopsy versus cleavage stage biopsy and blastocyst transfer for preimplantation genetic diagnosis of beta-thalassaemia: a pilot study. *Hum Reprod*. 2007;22(5):1443–9. doi: [10.1093/humrep/dej506](https://doi.org/10.1093/humrep/dej506) [PubMed: 17261575].

14. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. *The Lancet*. 2004;363(9421):1633–41. doi: [10.1016/s0140-6736(04)16209-0](https://doi.org/10.1016/s0140-6736(04)16209-0).

15. Verlinsky Y, Rechitsky S, Verlinsky O, Strom C, Kuliev A. Preimplantation testing for phenylketonuria. *Fertil Steril*. 2001;76(2):346–9. doi: [10.1016/s0015-0282(01)01912-4](https://doi.org/10.1016/s0015-0282(01)01912-4).

16. Harton GL, De Rycke M, Fiorentino F, Moutou C, SenGupta S, Traeger-Synodinos J, et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD. *Hum Reprod*. 2010;26(1):33–40. doi: [10.1093/humrep/deq231](https://doi.org/10.1093/humrep/deq231).

17. Peng W, Takabayashi H, Ikawa K. Whole genome amplification from single cells in preimplantation genetic diagnosis and prenatal diagnosis. *Eur J Obstet Gynecol Reprod Biol*. 2007;131(1):13–20. doi: [10.1016/j.ejogrb.2006.07.027](https://doi.org/10.1016/j.ejogrb.2006.07.027) [PubMed: 17157976].

18. Sermon K, De Rycke M. Single cell polymerase chain reaction for preimplantation genetic diagnosis: methods, strategies, and limitations. *Methods Mol Med*. 2007;132:31–42. doi: [10.1007/978-1-59745-298-4_4](https://doi.org/10.1007/978-1-59745-298-4_4) [PubMed: 17878074].